RESEARCH STUDIES & Clinical Trials

Clinical Trial ID: NCT03222609 A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis

Status

Open

Description

Objective

Treatment

Conditions

Bones and Joints

Phases

II (Cancer Control)

Therapies

Drugs

Age Group

Adult

Main Investiagtor

Norkin, Maxim

Practice

Bone Marrow

Scope

National

Participating Institutions

Baptist MD Anderson Cancer Center

Eligibility

Nct ID Number

NCT03222609

Secondary Trial ID Number

M16-109/AbbVie

Keywords

Treatment

More Information

clinicaltrials.gov

“The support team gave not only me but my family a sense of peace.”

—David Smith, Patient

At Baptist MD Anderson, you can rely on our cancer experts to deliver the complex, coordinated care needed to address your condition. Learn more about Patricia’s story as well as others from our patients.